Prevail Therapeutics Inc. (NASDAQ:PRVL) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 677,100 shares, a decline of 9.6% from the January 15th total of 748,800 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily volume of 109,800 shares, the short-interest ratio is presently 6.2 days.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fred Alger Management LLC acquired a new position in shares of Prevail Therapeutics in the 4th quarter valued at approximately $47,000. Barclays PLC acquired a new position in shares of Prevail Therapeutics in the 3rd quarter valued at approximately $47,000. Citigroup Inc. raised its position in shares of Prevail Therapeutics by 965.4% in the 4th quarter. Citigroup Inc. now owns 4,123 shares of the company’s stock valued at $65,000 after buying an additional 3,736 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Prevail Therapeutics in the 4th quarter valued at approximately $67,000. Finally, California State Teachers Retirement System acquired a new position in shares of Prevail Therapeutics in the 3rd quarter valued at approximately $142,000. 78.00% of the stock is owned by hedge funds and other institutional investors.

NASDAQ PRVL traded down $0.37 during trading on Friday, reaching $17.38. The company’s stock had a trading volume of 6,401 shares, compared to its average volume of 114,357. The company has a debt-to-equity ratio of 0.06, a quick ratio of 17.05 and a current ratio of 17.05. Prevail Therapeutics has a 12 month low of $7.41 and a 12 month high of $19.25. The firm has a 50 day moving average price of $17.63 and a 200 day moving average price of $13.42.

Prevail Therapeutics (NASDAQ:PRVL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.12). Analysts anticipate that Prevail Therapeutics will post -2.74 earnings per share for the current year.

PRVL has been the subject of a number of recent research reports. Cowen reissued a “buy” rating on shares of Prevail Therapeutics in a report on Tuesday, November 12th. Zacks Investment Research downgraded shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 14th. Finally, Wedbush reissued a “buy” rating and issued a $20.00 price objective on shares of Prevail Therapeutics in a report on Friday, November 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Prevail Therapeutics has an average rating of “Buy” and an average target price of $16.50.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Article: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.